Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis

Scutari, Rossana; Piermatteo, Lorenzo; Manuelli, M.; Iannetta, Marco; Salpini, Romina; Bertoli, Ada; Alteri, Claudia; Saccomandi, Patrizia; Bellocchi, Maria Concetta; Malagnino, Vincenzo; Teti, Elisabetta; Sforza, D.; Siragusa, Leandro; Grande, Michele; Sarmati, Loredana; Svicher, Valentina; Andreoni, Massimo; Ceccherini‐Silberstein, Francesca

doi:10.3390/life10110302

Cited by 15 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For SARS-CoV-2 RNA quantification by ddPCR, total RNA was extracted from 280 μL of samples using the QIAamp viral RNA mini kit (Qiagen, Hilden, Germany) according to manufacturer’s instruction and concentrated up to 10 μL by using Savant DNA SpeedVac (Thermo Fisher Scientific, Waltham, MA, USA). SARS-CoV-2 RNA was quantified by QX200TM Droplet DigitalTM PCR System (ddPCR, Biorad, Hercules, CA, USA) using an in-house assay, targeting the RdRP gene of SARS-CoV-2 as previously described [ 47 , 48 ]. The assay also targets the housekeeping gene RNAse P as internal control of amplification.…”

Section: Methodsmentioning

confidence: 99%

Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients

Zingaropoli

Iannetta

Piermatteo

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

Neurofilament light chain (NfL) is a specific biomarker of neuro-axonal damage. Matrix metalloproteinases (MMPs) are zinc-dependent enzymes involved in blood–brain barrier (BBB) integrity. We explored neuro-axonal damage, alteration of BBB integrity and SARS-CoV-2 RNA presence in COVID-19 patients with severe neurological symptoms (neuro-COVID) as well as neuro-axonal damage in COVID-19 patients without severe neurological symptoms according to disease severity and after recovery, comparing the obtained findings with healthy donors (HD). Overall, COVID-19 patients (n = 55) showed higher plasma NfL levels compared to HD (n = 31) (p < 0.0001), especially those who developed ARDS (n = 28) (p = 0.0005). After recovery, plasma NfL levels were still higher in ARDS patients compared to HD (p = 0.0037). In neuro-COVID patients (n = 12), higher CSF and plasma NfL, and CSF MMP-2 levels in ARDS than non-ARDS group were observed (p = 0.0357, p = 0.0346 and p = 0.0303, respectively). SARS-CoV-2 RNA was detected in four CSF and two plasma samples. SARS-CoV-2 RNA detection was not associated to increased CSF NfL and MMP levels. During COVID-19, ARDS could be associated to CNS damage and alteration of BBB integrity in the absence of SARS-CoV-2 RNA detection in CSF or blood. CNS damage was still detectable after discharge in blood of COVID-19 patients who developed ARDS during hospitalization.

show abstract

Section: Methodsmentioning

confidence: 99%

Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients

Zingaropoli

Iannetta

Piermatteo

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…An overall of 3651 samples, from 2825 patients and 145 controls, were extracted from the 39 included studies. The studies were conducted worldwide; 16 in Asia [ 12 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 ], 14 in Europe [ 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ], and 9 in North America [ 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 ]. A minority of studies (8) included control samples [ 21 , 28 , 29 , 33 , 38 , 47 , 54 , 56 ].…”

Section: Resultsmentioning

confidence: 99%

“…Other commonly used sources were the blood, plasma, saliva, oropharyngeal, sputum, and respiratory excretions. Some studies also reported the use of rectal, urine, and bronchoalveolar lavage (BAL) samples [ 30 , 44 , 45 ]. One study reported using colostrum samples [ 55 ].…”

Section: Resultsmentioning

confidence: 99%

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

Ishak

AlRawashdeh

Esagian

et al. 2021

JCM

View full text Add to dashboard Cite

Accurate detection of SARS-CoV-2, the pathogen causing the global pandemic of COVID-19, is essential for disease surveillance and control. Quantitative reverse transcription PCR (RT-qPCR) is considered the reference standard test for the diagnosis of SARS-CoV-2 by the World Health Organization and Centers for Disease Control and Prevention. However, its limitations are a prompt for a more accurate assay to detect SARS-CoV-2, quantify its levels, and assess the prognosis. This article aimed to systematically review the literature and assess the diagnostic performance of droplet digital PCR (ddPCR), also to evaluate its potential role in prognosis and management of COVID-19 patients. PubMed and Scopus databases were searched to identify relevant articles published until 13 July 2021. An additional PubMed search was performed on 21 October 2021. Data from the 39 eligible studies were extracted and an overall 3651 samples from 2825 patients and 145 controls were used for our qualitative analysis. Most studies reported ddPCR was more accurate than RT-qPCR in detecting and quantifying SARS-CoV-2 levels, especially in patients with low viral loads. ddPCR was also found highly effective in quantifying SARS-CoV-2 RNAemia levels in hospitalized patients, monitoring their disease course, and predicting their response to therapy. These findings suggest ddPCR could serve as a complement or alternative SARS-CoV-2 tool with emerging diagnostic, prognostic, and therapeutic value, especially in hospital settings. Additional research is still needed to standardize its laboratory protocols, also to accurately assess its role in monitoring COVID-19 therapy response and in identifying SARS-CoV-2 emerging variants.

show abstract

“…Apart from these, COVID-19 is found to trigger arthritis [200], dermatomyositis [131], glioma [188], and early onset of diabetes and severe metabolic complications [33]. Considering the facts that (i) all these NCDs and mental health conditions are found enriched at top ranks in our analysis along with several conditions, (ii) high confidence of our analysis (∼90%), (iii) most of our identified conditions are associated with severity of COVID-19, (iv) the bidirectional relationship between diabetes and COVID-19 [33], psychiatric disorder and COVID-19 [34], COVID-19 and cardiovascular system diseases [35], (v) presence of SARS-CoV-2 viral RNA in patients body for long time after recovery [20], and (vi) our “genetic remittance” assumption [43]; we hypothesize that in long-term, COVID survivors may develop various conditions we have identified in this analysis. However, as COVID-19 is a new disease, long-term observational studies are required on COVID-19 survivors to assess the long-term consequences of the SARS-CoV-2 infection.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, pathways that are activated during the infection remains switched on for a considerable duration within the host and subsequently develop clinical symptoms in long term. The RNA of the SARS-CoV-2 remains active in the COVID-19 survivors for more than 75 days [20] and thus the virus can maintain the upregulation of these omics profile for long periods and as long-term consequences of it, the non-communicable disease (NCD) pathways associated with these upregulated omics profile also remain active and subsequently will trigger the development of the clinical symptoms/phenotypes in long term.…”

Section: Methodsmentioning

confidence: 99%

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

Barh

Tiwari

Andrade

et al. 2020

Preprint

View full text Add to dashboard Cite

Till date the comprehensive clinical pictures, comorbid conditions, and long-term complications of COVID-19 are not known. Recently using a multi-omics-based strategy, we have predicted the drugs for COVID-19 management with ∼70% accuracy. Here, using a similar multi-omics-based bioinformatics approach and three-ways of analysis, we identified the symptoms, comorbid conditions, and short, mid and possible long-term complications of COVID-19 with ∼90% precision. In our analysis (i) we identified 27 parent, 170 child, and 403 specific conditions associated with COVID-19. (ii) Among the specific conditions, 36 are viral and 53 short-term, 62 short to mid to long-term, 194 mid to long-term, and 57 are congenital conditions. (iii) At a cut off “count of occurrence” of 4, we found ∼ 90% of the enriched conditions are associated with COVID-19. (iv) Except the dry cough and loss of taste, all other COVID-19 associated mild and severe symptoms are enriched. (v) Cardiovascular, pulmonary, metabolic, musculoskeletal, neuropsychiatric, kidney, liver, and immune system disorders are found as top comorbid conditions. (vi) Specific diseases such as myocardial infarction, hypertension, COPD, lung injury, diabetes, cirrhosis, mood disorders, dementia, macular degeneration, chronic kidney disease, lupus, arthritis etc. along with several other diseases are also enriched as top candidates. (vii) Interestingly, many cancers and congenital disorders associated with COVID-19 severity are also identified. (viii) Arthritis, dermatomyositis, glioma, diabetes, psychiatric disorder, cardiovascular diseases having bidirectional relationship with COVID-19 are also found as top ranked conditions. Based on the accuracy (∼90%) of this analysis, long presence of SARS-CoV-2 RNA in human, and our previously proposed “genetic remittance” assumption, we hypothesize that all the identified comorbid conditions including the short-long-mid and mid-long non-communicable diseases (NCDs) could also be long-term consequences in COVID-19 survivors and warrants long-term observational studies.

show abstract

Long-Term SARS-CoV-2 Infection Associated with Viral Dissemination in Different Body Fluids Including Bile in Two Patients with Acute Cholecystitis

Cited by 15 publications

References 25 publications

Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients

Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients

Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review

A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19

Contact Info

Product

Resources

About